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Abstract 
Background and objectives: There are several formulations of propofol available to the 
anesthesiologist for clinical use. The aim of this study was to analyze the physicochemical 
properties, pharmacodynamic effect, and pharmaceutical and clinical equivalence of the reference 
drug propofol as well as a similar formulation.
Method: Sixteen volunteers were enrolled in this randomized, double-blind, and paired study of 
Diprivan® and Propovan® formulations. Formulations were given as target-controlled infusion 
with target concentration of 3.0 μg.mL-1 for 15 minutes. Variables studied were the area under 
the curve (AUC) of the bispectral index (BIS) graph regarding time, minimum BIS reached and 
time to reach it, and recovery time. The two formulations were sent to analysis of particle size 
of lipid emulsion, surface potential, and active principle quantiﬁ cation.
Results: There was no difference between the formulations when comparing AUC, minimum 
BIS reached and time to reach it. The similar formulation recovery time was lower compared 
to the reference formulation (eight and 10 min, respectively, p = 0.014). Mean particle size of 
lipid emulsion, surface potential, and active ingredient quantiﬁ cation were similar for both 
formulations.
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Conclusion: There was no clinically signiﬁ cant difference between the use of propofol, reference 
Diprivan®, and the similar Propovan® during infusion. However, the recovery time was longer 
with the reference drug. Although analysis of both formulations studied show similar results 
regarding its physicochemical characterization, further studies should be conducted to justify 
this difference.
© 2013 Associação Brasileira de Psiquiatria. Published by Elsevier Editora Ltda. 
Introduction
There are various formulations of propofol available for clini-
cal use in Brazil. Despite strict regulations by the National 
Health Surveillance Agency (ANVISA) regarding inspection 
and quality control of drugs, many questions remain about 
the real clinical equivalence between brands of existing 
drugs.
In clinical practice, many anesthesiologists empirically 
evaluated differences between propofol presentations, as 
the desired pharmacodynamic effect is only achieved with 
different doses of commercially available presentations of 
the same content.
Propofol (2,6-diisopropylphenol, 178.27 g.mol-1, CAS: 
2078-54-8) (Figure 1) is an intravenous anesthetic with 
hypnotic properties. It is widely used in clinical practice 
for anesthesia induction and maintenance due to its rapid 
onset of action, short duration, and few adverse effects 
when given in therapeutic doses. Its rapid onset of action 
is due to its easy passage through the blood brain barrier 
and almost immediate action on the central nervous sys-
tem, mainly because of its high lipophilicity. It is usually 
presented as a lipid emulsion due to its very low water 
solubility. Commercial formulations of propofol emulsions 
are isotonic and generally consist of 10 or 20 mg.mL-1 of 
propofol, 100 mg.mL-1 of soybean oil, 22.5 mg.mL-1 of 
glycerol, 12 mg.mL-1 of egg yolk lecithin, 0.005% of ede-
tate disodium (EDTA), water and sodium hydroxide for pH 
adjustment (pH 7.0-8.5) 1. The physicochemical properties 
of emulsions, such as lipid composition, type of emulsiﬁ er, 
size and level of particle organization, surface potential, 
and pH, are directly related to the formulation performance 
and pharmacokinetic and dynamic behavior of the embed-
ded active substance.
The aim of this study was to systematic and comparatively 
analyze the physicochemical properties, pharmacodynamic 
effect (hypnosis), and pharmaceutical and clinical equiva-
lence of the reference drug propofol (Diprivan® - AstraZeneca 
do Brasil Ltd) and a similar formulation (Propovan® - Cristália 
Produtos Químicos Farmacêuticos Ltd). The tested hypothesis 
is that Diprivan® may differ from Propovan® regarding the 
hypnotic effect and pharmacokinetic characteristics (i.e., 
the main physicochemical and clinical characteristics), and 
that such differences are related to the differences in the 
average size of particles and active ingredient concentration 
in the formulations studied.
Material and method
Clinical study
After approval by the Research Ethics Committee and obtain-
ing signed informed consent from sixteen healthy adult male 
subjects were enrolled in the study. The selected volunteers 
were allocated into two groups (double-blind, paired) and 
presented themselves at a predetermined location, with 8 
hours fasting.
All volunteers were monitored with electrocardiogram (in 
leads DII and V1), peripheral oxygen saturation, noninvasive 
mean arterial pressure, and bispectral index (BIS). Oxygen 
was administered using a nasal catheter (2.0 L.min-1) and 
a right antecubital vein puncture performed, connecting a 
venous catheter ﬁ lled with one of the propofol formulations. 
Saline infusion was not administered at any time to break 
the fast or replace insensible losses.
Diprivan® and Propovan® formulations were delivered 
by target-controlled infusion using Marsh pharmacokinetic 
model (Ke0 0.26 min-1) and minimum washout of 72 hours.
Infusion management and clinical variables evaluation 
were performed using the program Anestfusor (University of 
Chile, Santiago, Chile) coupled to an infusion pump (Pilot II 
Anaesthesia, Fresenius Kabi, Germany) and BIS (version XP, 
Aspect Medical, USA).
Figure 1  Propofol.
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This was a randomized, double blind trial with two 
comparative periods between formulations (Diprivan® and 
Propovan®). To avoid biased behaviors, each syringe was 
ﬁ lled and identiﬁ ed as formulation “A” or “B” and handed to 
the anesthesiologist responsible for the administration.
The samples of Diprivan® (Lot No. X09144B) and 
Propovan® (Lot No. 10075239) used in the study were stored 
according to manufacturer’s recommendations.
Propofol was infused at target plasma concentration of 
3.0 μg.mL-1. After 15 minutes infusion, the target plasma 
concentration of propofol was reduced to zero.
The concentration values of propofol in the expected site 
of action (Ce) and BIS values were recorded at 60-second 
intervals during infusion and for 10 minutes after infusion.
For each subject, the degree of hypnosis was found by 
calculating the area under the curve (AUC) of the BIS graph 
regarding time by the sum of the trapezoid areas. We also 
assessed the minimum BIS reached during the experiment 
and the time required for its occurrence.
Recovery time was regarded as the period between the 
end of infusion and the time the patient had reached a BIS 
value of 70.
Statistical analysis of parametric attributes was per-
formed using the paired Student’s t-test and expressed as 
mean and standard deviation. The difference was considered 
statistically signiﬁ cant when p < 0.05.
The correlation between the predicted plasma concentra-
tion of propofol, site of action, and BIS for both reference 
propofol and similar was calculated using Pearson’s cor-
relation coefﬁ cient (ρ). We also calculated the coefﬁ cient 
of determination (R2) for the different correlations, which 
shows the proportion of variance (ﬂ uctuation) of one variable 
that is predictable from another variable. It represents the 
percentage of data closer to the line of best ﬁ t.
Physicochemical analysis
Both formulations of propofol were subjected to analysis 
of the mean particle size of lipid emulsion, Zeta poten-
tial (surface potential), pH, and quantiﬁ cation of active 
ingredient.
Analyses of mean particle size and zeta potential were 
performed using the dynamic light scattering equipment 
(Zetasizer Nano ZS - Malvern Instruments, U.K.), and pH 
measurements using the TA 350 pHmeter (Alfakit, Brasil) 
with universal glass electrode.
Microscopic image of the two lipid emulsion formulations 
of propofol was obtained by smear slide/coverslip and direct 
viewing under a light microscope (Olympus Optical IX70) 
ampliﬁ ed a thousand times and 30% obscuration.
Quantitative analysis of the active ingredient, propofol, 
in Diprivan® and Propovan® was performed by liquid chro-
matography coupled with mass spectrometry (LC-MS). Both 
formulations were diluted in isopropanol (IPA) to generate 
the respective stock solutions of 1.0 mg.mL-1. Solutions were 
prepared by serial dilutions of stock solutions. The calibra-
tion curve was constructed with eight concentration levels 
doubled (1.0-1,000 ug.mL-1). Formulations were studied twice 
(on different days) with batches of samples at a concentration 
of 100 ug.mL-1 in quintuplicate and injected volume of 1.0 uL. 
Chromatographic separation was performed over a Luna C18 
column (150x2 mm, 3 u – Phenomenex, USA) eluted with 
acetonitrile and 10 mM ammonium acetate in water (45:55, 
respectively), in isocratic mode at a ﬂ ow rate of 400 uL.min-1 
and using an Agilent 1200 chromatograph. Analyte retention 
time was 4.6 minutes, in analytical run of 7.0 minutes. Mass 
detection was made using a spectrometer QTRAP 3200 (Sciex/
Applied Bisystems, USA), with interface Turbo-V® (ESI-) in SIM 
mode (Single Ion Monitoring) and ion monitoring m/z = 177.2 
(corresponds to deprotonated propofol [M-H] -).
Results
The mean age, weight, and height of the subjects were 
30 years (25-43), 82 kg (71-94), and 177 cm (170-188), 
respectively.
Figure 2 shows the mean values of BIS regarding time 
during infusions of Diprivan® and Propovan®. Table 1 shows 
the pharmacodynamic variables. Figure 3 shows the values 
of plasma concentration (Cp) at the expected site of action 
(Ce) of propofol and BIS values obtained with Diprivan® and 
Propovan® infusions. Table 2 shows the correlation values 
between Ce, Cp, and BIS values obtained with Diprivan® 
and Propovan® infusions. Table 3 shows the results of quan-
titative analysis of drugs. The average particle size of lipid 
emulsion of Diprivan® and Propovan®, Zeta potential, and 
pH are shown in Table 4. Figures 5 and 6 show the particle 
size dispersion of propofol emulsion and Zeta potential dis-
tribution. Figures 7 and 8 show the images obtained by light 
microscopy with a magnifying power of 1,000x.
Discussion
The aim of this study was to perform a complete evaluation of 
the reference product (Diprivan®) and the product similar to 
propofol most used in Brazil (Propovan®), with the intention 
of demonstrating scientiﬁ cally whether there is difference 
100
90
80
70
60
50
40
BIS
0 5 10 15 20 25 30min
Diprivan Propovan
Figure 2  Mean Values of BIS regarding Time during Infusions 
with Diprivan® and Propovan®.
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There was no difference in clinical examination regarding 
the degree and depth of hypnosis caused by both studied 
medications, as the area under the time curve of BIS mean 
values showed no signiﬁ cant difference (p = 0.246) (Table 1). 
There was also no signiﬁ cant difference between BIS mini-
mum values (maximum effect achieved in volunteers) and 
time to reach this maximum effect (p = 0.742 and p = 0.3, 
respectively) (Table 1).
Studies conducted in other countries comparing the phar-
macodynamic efﬁ cacy of Diprivan® and generic formulation 
of propofol show similar results 2-4. However, the recovery 
time (BIS = 70) was 20% lower for Propovan® compared to 
Diprivan® (eight and 10 minutes, respectively). No differ-
ence that could explain this fact was found among the physi-
cochemical variables tested. Perhaps further study of the 
lipid emulsion components may explain this difference.
Interestingly, a study comparing generic sevoﬂ urane with 
Sevorane® showed that the time to spontaneous eye open-
ing and handshake on verbal command was lower with the 
generic formulation 5.
According to other authors, there is a strong correlation 
between the predicted concentration at the site of action 
of propofol (Ce) and BIS 6,7. In this study, the propofol Ce 
predicted by Marsh pharmacokinetic model (Ke0 0.26 min-1) 
showed a strong correlation with BIS values for the two 
formulations used. However, the plasma concentration of 
propofol (Cp) predicted by the same model showed mod-
erate correlation (0.3 < ρ < 0.7) with BIS values for both 
formulations, corroborating previously published data 6,8,9 
(Table 2 ). This is basically caused by the delay in the bal-
ance between Cp and Ce in the central nervous system, 
called effector site 10.
Figure 3 shows the synchrony between pharmacokinetics 
and pharmacodynamics achieved by this pharmacokinetic 
model, both in the use of the reference and similar medica-
tions. The study shows that both formulations behave simi-
larly even in target-controlled infusion. This fact was also 
seen in another study of propofol, which showed that the 
pharmacokinetic model predictability does not change with 
the use of generic formulation 11.
The quantiﬁ cation of propofol – active ingredient in both 
formulations – was similar. The technique of choice for drug 
quantitation by LC-MS 12,13 and the method used met the 
required criteria for accuracy and precision. The variation 
between the mean concentration of propofol in the analyzed 
formulations (0.98%) is within the content variation criteria 
recommended by ANVISA for drugs in bioequivalence studies 
or relative bioavailability (< 5%) 14 (Table 3 and Figure 4).
Factors related to lipid emulsion chemical and physical 
structure may also change its clinical efﬁ cacy, stability, and 
safety.
Chemically, benzene ring and isopropyl group make the 
propofol molecule highly lipophilic (octanol/water partition 
coefﬁ cient log p = 4.16) 15 and slightly soluble in water, there-
fore, its presentation in the form of salt is unlikely. Thus, 
propofol is usually found in emulsion formulation, such as a 
white emulsion, oil-water (discontinuous or dispersed phase/
continuous phase), composed mainly of soybean oil, glycerol, 
and egg yolk lecithin 16. Soybean oil has an important role in 
propofol solubility for preparing formulations. Because of its 
lipophilicity, propofol is found in high concentration in the 
dispersed phase and at low concentration in the continuous 
Table 1  Pharmacodynamic Variables Expressed in Mean 
and Standard Deviation.
Diprivan® Propovan® p
Total area 1,453.8 ± 205.9 1,498.7 ± 210.4 0.246
Area during infusion 886.7 ± 112.7 901.3 ± 134.3 0.535
Recovery area 545.6 ± 95.1 574.9 ± 81.8 0.100
Minimum BIS 37.9 ± 10.3 38.3 ± 9.8 0.742
Time to minimum 
BIS (min)
14.3 ± 2.8 13.7 ± 2.7 0.300
Recovery time (min) 10.0 ± 4.6 8.0 ± 3.5 0.014
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Figure 3  Plasma Concentration (Cp) Predicted Concentration 
of Propofol in Site ofAction (Ce), and Bispectral Index (BIS) 
Values with Infusion of Diprivan® and Propovan®.
Table 2  Correlation between Ce, Cp, and BIS values with 
Diprivan® and Propovan®.
p R2
Ce and BIS – Diprivan 0.972 0.94
Ce and BIS – Propovan 0.988 0.97
Cp and BIS – Diprivan 0.437 0.19
Cp and BIS – Propovan 0.523 0.27
Ce: predicted concentration at the site of action of propofol; 
Cp: predicted plasma concentration of propofol; ρ: Pearson’s 
coefﬁ cient, R2: coefﬁ cient of determination; BIS: Bispectral Index.
between both formulations, especially regarding the hyp-
notic/anesthetic effect, active ingredient concentration, 
and characteristics of lipid emulsion.
First, we performed a clinical examination in healthy vol-
unteers.  Then, we proceeded to a thorough physicochemical 
evaluation of the presentations involved.
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Table 3  Results of Quantitative Analysis of Propofol by LC-MS in Diprivan® and Propovan® with Coefﬁ cients of Variation 
(CV%) and the Intra- and Inter-day Means.
Calibration Curve Data
Calibration range 1.00 – 1,000 ug.mL-1
Regression type Linear (y = ax + b) with weighting (1/x)
Equation y = 350x – 1.54
Coefﬁ cient of 
determination  
r = 0.9999
Accuracy 93 – 105%
Precision ± 1.5%
Results
Samples (100 ug.mL-1) Propovan
(day 1)
Propovan
(day 2)
Diprivan
(day 1)
Diprivan
(day 2)
Intra-day average
 (ug.mL-1)
101 104 102 105
CV% 2.6 5.2 3.0 6.7
Inter-day average
 (ug.mL-1)
103 104
CV% 4.3 5.0
Variation
Diprivan = reference
Propovan = test
-0.98%
LC-MS: Mass spectrometry.
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Figure 4  Chromatogram Overlay of Diprivan® and Propovan® 
regarding Active Ingredient Propofol.
are thermodynamically unstable and do not form spontane-
ously. Thus, to maintain stability and homogeneity, energy 
is required for its formation and the use of combined emul-
sifying agents (surfactants) to increase the kinetic stabil-
ity of preparation. Stability of emulsions is guaranteed by 
controlling the interfacial tension of the phases, obtaining 
a mechanically stable ﬁ lm, controlling the electrostatic or 
steric barrier and low volume of the dispersed phase, and 
obtaining uniform small particles.
In the formulations studied, the lecithin in egg yolk acts 
as an emulsiﬁ er, reduces surface tension between phases, 
and enables the formation of tiny disperse and stable oil 
droplets in the aqueous phase (continuous phase - larger 
volume of emulsion).
Only a limited number of emulsiﬁ ers are considered 
safe for use in parenteral and intravenous administrations. 
Compared with the synthetic options, lecithin is a good 
choice for this purpose because it is well tolerated, totally 
biodegradable and metabolized, as it is part of biological 
membranes.
Lecithins are mainly composed of phospholipids [66-76% 
phosphatidylcholine (FC); 15-24% phosphatidylethanolamine 
(PE), and 1% phosphatidylserine (PS)]. Because it is an am-
phiphilic lipid, it has a hydrophilic “head” (polar phosphates) 
and hydrophobic “tail” (nonpolar fatty acids). It is this fea-
ture that makes the link between oil and water in emulsion 
formation, which plays an important role in stabilizing the 
formulations. They act by promoting a negative electrostatic 
charge on the surface of the droplets, repelling them. The 
phase 17. Among the study drugs, Diprivan® contains in its 
formulation 0.005% EDTA, which has bacteriostatic proper-
ties. However, this agent does not affect the quality of 
anesthetic hypnosis 17.
According to the International Union of Pure and Applied 
Chemistry (IUPAC), emulsions are dispersions of immiscible 
liquids, oil in water (O/W) or water in oil (W/O). Preparations 
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magnitude of this surface potential (voltage) is quantiﬁ ed as 
Zeta potential. Emulsions are considered stable when Zeta 
potential varies between 50-40 mV 18,19.
In the present study, both propofol formulations showed 
very stable lipid emulsions, as Zeta potential was -54 and 
48.4 mV (Diprivan® and Propovan®, respectively, Table 4). 
This emulsion stability results from the formation of a 
mechanical barrier between the oil droplets and aqueous 
phase and electrostatic repulsion forces between droplets. 
The breaking of one of these forces causes degradation of 
emulsion and separation of phases 17.
Important factors - such as pH - may change the Zeta 
potential making the emulsion unstable and, thus, decreasing 
the repulsive forces and results in coalescence and formation 
of large droplets. At acidic pH, Zeta potential may reach val-
ues close to zero, making the emulsion rather unstable 17.
Although the pH value found for Propovan® was equal to 
6.92 (acid), it was not enough to alter the emulsion stability, 
as the Zeta potential values were within the recommended 
range (Table 4).
One study showed that in preparations of a generic pro-
pofol with pH between 4.0 and 5.0, the emulsion became 
unstable and with larger droplets of 5 mm after four hours of 
stirring (300 vibrations.min-1). However, even with a stirring 
period of 16 hours, the emulsion of Diprivan® (pH 7.0-8.5) 20 
remained stable.
The emulsion size of the oil particle is another key factor 
for the safety and stability of formulations. Emulsions contain-
ing droplets larger than 5-7 μm may cause thromboembolic 
events 21. The average size of droplets acceptable for pro-
pofol formulations must be less than 1.0 μm (1,000 nm) 18,22. 
Propofol emulsion formulations for commercial use have an 
average droplet size between 100 and 300 nm 20,23.
By the technique of dynamic light scattering, we found 
that the average emulsion droplet size between formulations 
was similar (Diprivan® 180.5 nm and Propovan® 177 nm, 
Table 4). However, the lipid emulsion of Diprivan® was more 
homogenous than the Propovan®, as the average dispersion 
was lower with Diprivan® (Figures 5, 7, 8).
When in contact with the bloodstream, the propofol 
dissolved in oily medium (within droplet) is rapidly diffused 
in the plasma. Consequently, the smaller the emulsion par-
ticle, the greater the surface area of contact with blood, 
the greater the release rate of the active ingredient, and 
the lower the latency 17.
Because the average droplet size of emulsions was similar, 
there was no difference in latency between both formula-
tions. According to the clinical study performed, there was 
no signiﬁ cant difference in maximum effect reached (simi-
lar minimum values of BIS) and time required to reach this 
maximum effect.
Other authors have shown that clinical observations of 
propofol inconsistent activity may be related to individual 
differences in lipoprotein proﬁ le, enzyme activity or genetic 
diseases, instead of problems related to the pharmaceutical 
preparation itself 24.
A strong correlation was also found between the con-
centration of propofol in the site of action predicted by 
the Marsh pharmacokinetic model and bispectral index with 
both formulations. Qualitative analysis showed that both 
formulations present the same amount of active ingredient 
(propofol). The lipid emulsions of the formulations studied 
were stable, with similar average droplet size and surface 
potential and within the safe range.
In conclusion, with the dose used, there were no clini-
cally signiﬁ cant differences between propofol (reference 
drug, Diprivan®) and generic drug Propovan® during infusion. 
However, the recovery time is longer with the reference drug. 
Although the physicochemical analysis of both formulations 
show similar results, perhaps further studies of other lipid 
emulsion components may justify this difference.
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Figure 5  Size Distribution by Intensity.
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Table 4  Average Particle Size of Emulsions, Zeta Potential, and pH of Propofol Emulsion.
Diprivan® Propovan®
Average particle size (nm) 180.5 (78.8 – 458.7) 177.0 (68.06 – 615.1)
Zeta Potential (mV) -54.0 -48.4
pH 7.35 6.92
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Figure 7  Image obtained by light microscopy with a 
magnifying power of 1,000 x.
Figure 8  Image obtained by light microscopy with a 
magnifying power of 1,000 x.
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